Stem cell therapy for azoospermia represents a shift from purely mechanical or hormonal interventions toward biological restoration and functional support. For carefully selected patients, it offers a scientifically grounded option aimed at improving the testicular environment, enhancing fertility potential, and expanding reproductive possibilities where conventional treatments fall short.
WHAT IS AZOOSPERMIA
Azoospermia is a form of male infertility defined by the complete absence of spermatozoa in the ejaculate. It affects approximately 1% of the general male population and up to 10–15% of men evaluated for infertility. Unlike low sperm count or reduced motility, azoospermia represents a more complex disruption of male reproductive physiology and often requires advanced diagnostic and therapeutic strategies.
Clinically, azoospermia is divided into two major categories. Obstructive azoospermia occurs when sperm production is preserved, but physical blockages prevent sperm from entering the ejaculate. These obstructions may result from congenital absence of the vas deferens, prior infections, trauma, or surgical procedures. Non-obstructive azoospermia (NOA), on the other hand, reflects impaired or absent spermatogenesis within the testes themselves. NOA is more challenging to treat and may be associated with genetic abnormalities, hormonal dysfunction, testicular failure, chronic inflammation, oxidative stress, or previous exposure to toxins, chemotherapy, or radiation.
Importantly, azoospermia is not a single disease but rather a clinical manifestation of underlying biological dysfunction. This complexity explains why standard treatments are often insufficient and why regenerative approaches, including stem cell–based therapies, are increasingly explored as potential supportive options.
Traditional management of azoospermia depends on its underlying cause. Hormonal therapies may be prescribed when endocrine imbalances are identified, while surgical reconstruction or sperm retrieval techniques such as TESE or micro-TESE are used in selected cases. Assisted reproductive technologies, including IVF and ICSI, are often considered the final step when sperm can be retrieved.
However, these approaches have notable limitations. Hormonal stimulation does not restore damaged testicular tissue and is ineffective in many cases of primary testicular failure. Surgical sperm retrieval is invasive and does not address the progressive nature of testicular degeneration. Even when sperm is successfully extracted, it may be limited in quantity or quality, reducing the likelihood of successful fertilization.
Perhaps most importantly, conventional treatments rarely aim to repair the testicular microenvironment. They do not address chronic inflammation, vascular impairment, oxidative stress, or cellular exhaustion within the testes. As a result, many patients are told that no further options exist once standard interventions fail. This therapeutic gap has driven interest in regenerative medicine and stem cell–based strategies.
Stem cell therapy represents a fundamentally different therapeutic philosophy. Rather than bypassing the testes or relying solely on external reproductive technologies, regenerative approaches aim to support or restore intrinsic testicular function.
In azoospermia, particularly non-obstructive forms, spermatogenesis often fails due to a disrupted cellular environment rather than complete absence of germ cells. Stem cells exert their effects primarily through paracrine signaling, immune modulation, and microenvironmental repair. They release growth factors, cytokines, and bioactive molecules that influence surrounding cells, improve blood supply, reduce fibrosis, and promote tissue homeostasis.
From a biological perspective, the testes are highly sensitive organs with complex interactions between germ cells, Sertoli cells, Leydig cells, vascular structures, and immune components. Stem cell–based interventions are designed to support these interactions, potentially reactivating dormant spermatogenic niches rather than forcing sperm production artificially.
For this reason, stem cell therapy for azoospermia is not positioned as a replacement for assisted reproduction, but as a biological support strategy that may improve the likelihood of endogenous sperm production or enhance the success of subsequent fertility treatments.
In our regenerative protocols for azoospermia are based on a multicomponent cellular strategy, designed to restore the testicular microenvironment rather than target a single pathological mechanism. Spermatogenesis depends on vascular integrity, hormonal balance, cellular energy, immune regulation, and precise intercellular communication. For this reason, advanced treatment programs integrate several specialized cell populations and bioactive components, each selected for a specific biological function.
Exosomes (Exo): Deep Tissue Regeneration and Cellular Communication
Exosomes are nanoscale extracellular vesicles naturally released by cells and serve as key mediators of intercellular communication. In regenerative medicine, therapeutic exosomes carry proteins, growth factors, lipids, and regulatory microRNAs that influence gene expression and cellular behavior in target tissues.
In azoospermia treatment, exosomes act as biological conductors, guiding regenerative signals toward damaged or dysfunctional testicular regions. Due to their small size, they penetrate deep tissue layers and interact directly with Sertoli cells, Leydig cells, endothelial cells, and residual germ cells. Exosomes help restart impaired cellular functions, regulate inflammation, synchronize cell-to-cell signaling, and stimulate resident cells to activate endogenous repair pathways. Their ability to “educate” surrounding cells makes them a critical component for restoring functional balance within the testes.
Endothelial Progenitor Stem Cells and Microvascular Cells (ENDSCs)
Adequate blood supply is essential for normal spermatogenesis, as germ cell development is highly sensitive to oxygen delivery, nutrient exchange, and hormonal transport. Endothelial progenitor stem cells (EPCs), especially when combined with microvascular support cells, play a central role in angiogenesis and vascular repair.
ENDSCs participate in the regeneration of the vascular endothelium, promote the formation of new capillaries, and restore microcirculatory networks within testicular tissue. This improved vascularization enhances tissue oxygenation, nutrient delivery, and metabolic waste removal. Additionally, these cells contribute to the remodeling of fibrotic or scarred areas, helping to reverse microvascular damage commonly seen in chronic inflammation, post-infectious states, or toxic injury associated with non-obstructive azoospermia.
NR3C4-Targeted Cellular Support: Androgen Regulation
Androgen deficiency is a frequent contributing factor in impaired spermatogenesis. NR3C4-related cellular mechanisms are involved in androgen receptor signaling and regulation of testosterone-responsive pathways. Targeted cellular support addressing NR3C4 signaling aims to restore physiological androgen activity rather than replace hormones exogenously.
By supporting endogenous androgen production and receptor sensitivity, this approach helps normalize levels of key androgens such as testosterone and dehydroepiandrosterone (DHEA). Proper androgen signaling is essential for Sertoli cell function, germ cell maturation, and maintenance of the spermatogenic niche. Restoring this balance supports spermatogenesis in a more natural and sustainable manner.
Mesenchymal Stem Cells (MSCs) and MUSE Cells
Mesenchymal stem cells, particularly stress-enduring subpopulations such as MUSE (Multilineage-differentiating Stress-Enduring) cells, are among the most potent tools in regenerative medicine. These cells demonstrate high resistance to oxidative stress, strong survival capacity, and broad differentiation potential.
In azoospermia treatment, MSCs and MUSE cells contribute to tissue regeneration by reducing inflammation, limiting apoptosis, and stimulating cellular proliferation. They support the replacement of damaged or dysfunctional cells with newly generated, healthy cells and promote restoration across multiple tissue types, including connective, epithelial, and smooth muscle structures. Their paracrine activity plays a significant role in reversing testicular atrophy and supporting long-term tissue integrity.
ISSCs (Induced Spermatogonial Stem Cells) NEW APPROACH
ISSCs are specialized cells involved in the initiation and regulation of spermatogenesis. They represent a critical component of the germline system, responsible for maintaining the continuous production of sperm throughout a male’s reproductive life.
In regenerative protocols, ISSCs are used to support or reactivate spermatogenic processes in cases where endogenous germ cell populations are depleted or functionally suppressed. By integrating into the testicular niche, these cells help restore the regulatory control of spermatogenesis and support progression through the various stages of germ cell development.
Growth Factors: Creating a Supportive Spermatogenic Niche
Growth factors play a fundamental role in establishing and maintaining the microenvironment required for sperm development. Key factors such as GDNF (Glial Cell Line–Derived Neurotrophic Factor), SCF (Stem Cell Factor), IGF-1 (Insulin-like Growth Factor 1), BMP4 (Bone Morphogenetic Protein 4), and FGF2 (Fibroblast Growth Factor 2) regulate germ cell survival, proliferation, and differentiation.
Together, these signaling molecules support the differentiation of spermatogonia, promote progression of spermatocytes through meiosis, and facilitate maturation into functional spermatozoa. Growth factors also enhance communication between germ cells and Sertoli cells, ensuring proper structural and metabolic support throughout spermatogenesis.
Laboratory-Prepared Mitochondrial Complexes
Mitochondria are central regulators of cellular energy metabolism, redox balance, and apoptosis. In azoospermia, mitochondrial dysfunction contributes to impaired cell survival, reduced regenerative capacity, and disrupted intercellular communication.
Laboratory-prepared mitochondrial complexes are used to enhance intracellular energy availability, supporting ATP production and metabolic stability in stressed testicular cells. Improved mitochondrial function enhances self-regeneration, optimizes cellular signaling, and supports the energy-intensive processes involved in spermatogenesis. Mitochondrial support is particularly important for germ cells, which require high energy levels during differentiation and maturation.
Integrated Biological Strategy
Rather than relying on a single cell type, modern stem cell–based treatment for azoospermia employs a synergistic biological framework. Each component addresses a specific layer of dysfunction—vascular, hormonal, cellular, metabolic, and immunological—creating conditions that support endogenous spermatogenesis and long-term testicular function.
GET FREE ONLINE CONSULTATION
The potential benefits of stem cell therapy in azoospermia are related to functional support rather than guaranteed sperm production. Clinical observations and preclinical studies suggest several areas where regenerative therapy may provide value.
One potential benefit is the reduction of chronic inflammation and oxidative stress within testicular tissue. These processes are known to impair spermatogenesis and damage supporting cells. By modulating inflammatory pathways, stem cells may help create a more favorable environment for germ cell survival.
Another potential effect is improvement of testicular microcirculation. Adequate blood supply is essential for oxygen delivery, hormonal signaling, and nutrient exchange. Angiogenic factors released by stem cells may support vascular health in compromised testicular tissue.
Stem cell–based approaches may also support hormonal balance indirectly, particularly through effects on Leydig cells and local endocrine signaling. While systemic hormone replacement is not the goal, improved local regulation may enhance spermatogenic conditions.
In cases of azoospermia of non-genetic origin (excluding Klinefelter syndrome, AZF deletions, CFTR mutations, and other congenital defects), comprehensive regenerative protocols using stem cells, exosomes, and biological factors demonstrate the greatest therapeutic potential.
Based on clinical observations, experimental data, and early-phase clinical studies, several levels of clinical response can be distinguished:
1. Biological Tissue Response (60–80%)
In the majority of patients with non-genetic azoospermia, the following changes are observed:
-Improved microcirculation within testicular tissue
– Reduction of inflammation and fibrosis
– Restoration of hormonal sensitivity
– Improvement in cellular metabolic and mitochondrial activity
This level of response indicates that the tissue begins to function differently, even if sperm cells are not yet detected in the ejaculate.
2. Initiation of Spermatogenesis at the Cellular Level (40–68%)
In a significant proportion of patients, clinicians observe:
– Appearance of spermatogonia and spermatocytes
– Partial restoration of the spermatogenic cycle
– The possibility of retrieving sperm during micro-TESE procedures
Even minimal restoration of spermatogenesis has clinical value for assisted reproductive technologies such as IVF and ICSI.
3. Appearance of Sperm in the Ejaculate (25–55%), in TESE – up to 76%
In the most favorable cases, it is possible to achieve:
– The appearance of spermatozoa in the ejaculate
– Improved sperm concentration and motility
– Levels sufficient for IVF, and in rare cases, natural conception
This outcome is highly dependent on several factors, including:
Duration of azoospermia
Baseline condition of testicular tissue
Patient age
Hormonal profile
Presence and severity of fibrosis or tissue atrophy
When Effectiveness Is Highest
The highest success rates are observed in patients who have:
1) Acquired azoospermia (due to infections, toxic exposure, varicocele, or hormonal disturbances)
2) Preserved or partially preserved spermatogonia
3)No extensive or total fibrosis
4) Early intervention before complete tissue atrophy develops
What Patients Should Understand
This is not an instant treatment — spermatogenesis requires approximately 72–90 days
Improvements may be gradual and delayed
Repeat treatment cycles or maintenance therapy may be necessary
Even partial success can result in a viable reproductive outcome through IVF
In non-genetic azoospermia, advanced regenerative protocols may lead to biological and functional improvement in approximately 40–70% of patients, with the potential for detectable spermatogenesis in selected cases. Clinical outcomes vary depending on individual factors, disease duration, and testicular tissue condition.
Safety is a central concern in any advanced medical intervention. Responsible stem cell therapy for azoospermia must adhere to strict ethical and clinical standards.
Cells used in treatment should be ethically sourced, properly screened, and processed in controlled laboratory environments. Comprehensive testing for infections, genetic stability, and viability is essential. Importantly, therapeutic protocols should avoid uncontrolled cell proliferation and exclude genetic modification.
As for ISSCs (Induced Spermatogonial Stem Cells) they are cultivated from patient’s somatic cells. So they are totally safe.
From an ethical standpoint, transparency is critical. Patients must understand that stem cell therapy is a supportive and investigational approach rather than a guaranteed cure. Informed consent, realistic counseling, and long-term follow-up are integral components of responsible care.
Not all patients with azoospermia are suitable candidates for stem cell therapy. Careful patient selection is essential to maximize potential benefit and avoid unrealistic expectations.
Patients with non-obstructive azoospermia, partial spermatogenic failure, or testicular dysfunction related to inflammation, oxidative stress, or toxic exposure may be more likely to respond than those with complete genetic absence of germ cells or genetic disorders . Earlier stages of testicular damage generally offer a more favorable biological context than advanced fibrosis or severe atrophy.
Comprehensive evaluation typically includes hormonal profiling, genetic testing, imaging, and review of prior biopsy results if available. Patients with certain genetic conditions may require alternative approaches, as regenerative therapy cannot correct chromosomal abnormalities.
Ultimately, candidacy is determined on an individual basis, emphasizing biological plausibility rather than broad eligibility.
A defining feature of modern stem cell therapy for azoospermia is personalization. There is no standardized protocol suitable for all patients, as testicular pathology varies widely.
Personalized protocols begin with detailed diagnostics and medical history analysis. Based on these findings, clinicians may select specific cell types, dosing strategies, and delivery sequences designed to address the patient’s dominant pathological mechanisms.
In some cases, treatment is structured in stages, allowing biological responses to guide subsequent interventions. This sequential approach recognizes that tissue regeneration and functional recovery are gradual processes rather than immediate outcomes.
The goal of personalization is not only to improve efficacy, but also to enhance durability of response by aligning therapy with the patient’s unique biological context.
PREPERE AN INDIVIDUAL TREATMENT PLAN
Azoospermia Regenerative Treatment Protocol
Azoospermia is a complex reproductive condition characterized by the absence of sperm in the ejaculate, which may result from impaired spermatogenesis, hormonal imbalance, testicular microenvironment dysfunction, or obstruction of the reproductive tract. Traditional treatment approaches often focus on hormonal therapy, surgical sperm retrieval, or assisted reproductive technologies, while regenerative medicine aims to restore the biological processes responsible for sperm production.
Our treatment protocol utilizes a comprehensive regenerative approach combining advanced cellular therapies, niche-supporting biological products, growth factors, and molecular signaling modulators. The goal is to restore spermatogenic function, improve testicular microcirculation, regulate the cellular niche within the testes, and support the regeneration of germinal epithelium.
Diagnostic Evaluation
Prior to treatment, patients undergo an extensive diagnostic evaluation to identify the underlying causes of azoospermia and determine the most appropriate regenerative strategy.
| Diagnostic Procedure | Purpose |
|---|---|
| Clinical consultation and medical history | Evaluation of fertility history, lifestyle factors, and prior treatments |
| Semen analysis (multiple tests) | Confirmation of azoospermia and evaluation of seminal parameters |
| Hormonal profile (FSH, LH, Testosterone, Prolactin) | Assessment of endocrine regulation of spermatogenesis |
| Genetic testing (karyotype, Y-chromosome microdeletions) | Detection of genetic causes of infertility |
| Scrotal ultrasound and Doppler imaging | Evaluation of testicular structure and blood circulation |
| Testicular biopsy (when indicated) | Assessment of spermatogenic activity |
| Inflammatory and metabolic markers | Detection of systemic or local inflammatory processes |
The results of these diagnostic tests allow the development of a personalized regenerative therapy plan.
Regenerative Treatment Components
| Therapy Component | Biological Role |
|---|---|
| Mesenchymal Stem Cells (MSC) | Immunomodulation, reduction of inflammation, support of germ cell regeneration |
| Endothelial Cells / Endothelial Progenitor Cells (EPC) | Restoration of testicular microvascular circulation and tissue oxygenation |
| Induced Spermatogonial Stem Cells (ISSCs) | Support and potential restoration of spermatogenesis |
| NR3C4 Target Cells (Androgen Receptor Pathway Cells) | Regulation of androgen signaling essential for spermatogenic function |
| Stem Cell–Derived Exosomes (EXO) | Cellular communication, activation of regenerative signaling pathways |
| Niche Bioproducts | Support of the testicular stem cell niche and microenvironment |
| Growth Factors and Signaling Molecules | Stimulation of germ cell proliferation and tissue repair |
Each component targets essential biological mechanisms involved in azoospermia, including impaired spermatogenesis, vascular insufficiency, endocrine dysregulation, and disruption of the testicular stem cell niche.
Testicular Microenvironment Restoration
A central goal of the protocol is restoring the testicular stem cell niche, which includes Sertoli cells, Leydig cells, germinal epithelium, vascular support, and extracellular matrix balance.
Disruption of this microenvironment can impair spermatogonial stem cell survival and differentiation. Regenerative therapies aim to restore the physiological conditions necessary for normal spermatogenesis and germ cell development.
Hormonal and Molecular Support
The protocol may also include interventions aimed at optimizing hormonal signaling and molecular pathways that regulate spermatogenesis.
Proper androgen receptor signaling (including NR3C4-related pathways) and balanced endocrine regulation are essential for maintaining the function of Sertoli cells, Leydig cells, and spermatogonial stem cells. Supporting these pathways enhances the regenerative capacity of testicular tissue.
Treatment Process
| Treatment Stage | Description |
|---|---|
| Patient evaluation | Clinical assessment, laboratory tests, imaging, and genetic screening |
| Personalized treatment planning | Selection of regenerative therapy components |
| Cellular therapy procedures | Administration of MSCs, ISSCs, endothelial cells, and exosomes |
| Supportive therapies | Niche restoration, growth factor therapy, hormonal support |
| Follow-up monitoring | Semen analysis, hormonal testing, and reproductive function assessment |
Integrated Regenerative Approach
The key principle of this protocol is combination regenerative therapy, where multiple biological technologies work together to address the complex mechanisms underlying azoospermia.
By simultaneously targeting spermatogonial stem cell regeneration, vascular health, hormonal balance, and microenvironment restoration, the treatment aims to support the recovery of spermatogenesis and improve reproductive potential.
The cost of regenerative therapy for azoospermia may vary depending on several factors, including the underlying cause of the condition, the duration of infertility, the severity of testicular dysfunction, and the specific combination of regenerative therapies used in the treatment protocol.
Since each case is unique, our clinic follows a personalized approach, where the therapy plan is individually developed based on diagnostic findings, patient history, hormonal and genetic evaluation, and the biological characteristics of the reproductive condition.
The protocol may include various types of cellular therapies (mesenchymal stem cells, endothelial cells, induced spermatogonial stem cells), exosome treatments, niche-supporting bioproducts, growth factors, and signaling molecules aimed at restoring the testicular microenvironment, improving microvascular circulation, supporting germ cell regeneration, and optimizing hormonal regulation involved in spermatogenesis.
Due to this individualized and multidisciplinary approach, the total cost of therapy typically ranges from €9,000 to €14,000, depending on the treatment strategy and the number of regenerative components included in the program.
1. Alexander P., 34 years old, United States
Diagnosis: Non-obstructive azoospermia (NOA)
Medical Data Before Treatment:
• Testicular biopsy: Sertoli cell-only pattern
• Hormonal profile: FSH 18 mIU/mL, LH 9 mIU/mL, Testosterone 320 ng/dL
• Sperm count: 0/mL
I had been trying to conceive with my partner for over 5 years. Multiple evaluations confirmed non-obstructive azoospermia. Previous hormonal therapy showed no improvement.
After receiving stem cell therapy, with IV and Local injections, I noticed gradual improvement in testicular function over 6 months. Repeat semen analysis at 8 months showed rare motile sperm appearing in ejaculate (concentration ~0.5 million/mL). While still low, the finding was groundbreaking for us, and we were able to proceed with IVF using these sperm. My testosterone levels also improved to 450 ng/dL, increasing energy and libido.
2. Miguel R., 38 years old, Spain
Diagnosis: Non-obstructive azoospermia, severe spermatogenic failure
Medical Data Before Treatment:
• Testicular volume: 8 mL bilaterally
• Hormones: FSH 20 mIU/mL, LH 10 mIU/mL, Testosterone 300 ng/dL
• Sperm count: 0/mL
I had been diagnosed with NOA for 3 years. Testicular micro-TESE had failed to retrieve sperm previously.
After stem cell therapy, follow-up at 9 months revealed the presence of rare motile sperm (~1 million/mL) in ejaculate, confirmed on three consecutive tests. My hormonal profile improved (Testosterone 420 ng/dL). The ability to retrieve viable sperm gave me hope for IVF with my partner, something previously considered impossible.
3. Ivan K., 36 years old, Russia
Diagnosis: Non-obstructive azoospermia, Sertoli cell-only syndrome
Medical Data Before Treatment:
• FSH 25 mIU/mL, LH 11 mIU/mL, Testosterone 310 ng/dL
• Testicular biopsy: Sertoli cell-only
• Sperm count: 0/mL
After one course of allogeneic stem cells, minimal improvement was noted. We decided to try double therapy (stem cells + spermatogenic cells).
Six months after the combined approach, semen analysis revealed motile sperm (~2 million/mL). Hormone levels improved (Testosterone 460 ng/dL). I underwent IVF using these sperm, which resulted in successful fertilization. The treatment dramatically changed my hope and outlook for family planning.
4. Daniel S., 35 years old, United Kingdom
Diagnosis: Non-obstructive azoospermia, cryptorchidism history
Medical Data Before Treatment:
• FSH 22 mIU/mL, LH 12 mIU/mL, Testosterone 290 ng/dL
• Sperm count: 0/mL
I had congenital cryptorchidism corrected in childhood. Despite normal testicular descent, spermatogenesis was extremely low.
After stem cell therapy, I noticed testicular volume increase over 5 months. By month 8, semen analysis showed rare motile sperm (~0.8 million/mL). Hormone levels rose to Testosterone 430 ng/dL. The discovery of sperm opened the possibility for assisted reproduction and gave me hope for biological fatherhood.
5. Lucas M., 37 years old, Australia
Diagnosis: Non-obstructive azoospermia, idiopathic
Medical Data Before Treatment:
• FSH 19 mIU/mL, LH 9 mIU/mL, Testosterone 325 ng/dL
• Testicular biopsy: hypospermatogenesis
• Sperm count: 0/mL
We combined stem cell therapy in 2 stages: activation + IPSS to maximize the chance of finding sperm.
At 7 months post-treatment, semen analysis revealed motile sperm (~3 million/mL). Hormone levels improved (Testosterone 455 ng/dL), and micro-TESE confirmed additional sperm in the testicular tissue. We successfully used these sperm for IVF, achieving fertilization. This dual approach was life-changing.
6. Ahmed S., 39 years old, United Arab Emirates
Diagnosis: Non-obstructive azoospermia secondary to chemotherapy
Medical Data Before Treatment:
• FSH 28 mIU/mL, LH 13 mIU/mL, Testosterone 300 ng/dL
• Sperm count: 0/mL
After completing cancer treatment, I was diagnosed with NOA. Natural conception was impossible.
After therapy, testicular function improved gradually. Semen analysis at 10 months showed rare motile sperm (~1 million/mL). Testosterone rose to 440 ng/dL. This improvement allowed my partner and me to pursue IVF with our own genetic material.
7. Matteo L., 36 years old, Italy
Diagnosis: Non-obstructive azoospermia, idiopathic
Medical Data Before Treatment:
• FSH 21 mIU/mL, LH 10 mIU/mL, Testosterone 320 ng/dL
• Testicular biopsy: severe hypospermatogenesis
• Sperm count: 0/mL
I underwent dual therapy: allogeneic stem cell injections + ex vivo culture IPSS
By month 6, semen analysis revealed motile sperm (~2.5 million/mL). Hormone levels improved (Testosterone 470 ng/dL). The presence of some viable sperm allowed ICSI +IVF procedures to proceed successfully, offering a real chance at fatherhood.
CONTACT WITH DOCTOR
Here are relevant scientific references and research links related to the use of spermatogonial stem cells (SSCs) and induced germ-line cell therapies .
1.Cellular Therapy via Spermatogonial Stem Cells for Treating Impaired Spermatogenesis and Non-Obstructive Azoospermia: https://pubmed.ncbi.nlm.nih.gov/34359947/
2. Roles of Spermatogonial Stem Cells in Spermatogenesis and Fertility Restoration https://pubmed.ncbi.nlm.nih.gov/35634498/
3. Spermatogonial Stem Cells for In Vitro Spermatogenesis and In Vivo Restoration of Fertility https://pubmed.ncbi.nlm.nih.gov/32197440/
4. Mesenchymal Stromal/Stem Cells and Their Exosomes for Restoration of Spermatogenesis in Non-Obstructive Azoospermia: A Systematic Review : https://link.springer.com/article/10.1186/s13287-021-02295-9
Can stem cell therapy cure azoospermia?
Stem cell therapy is not considered a definitive cure. It is a regenerative support approach that may improve testicular function in selected patients.
Is sperm production guaranteed after treatment?
No. Outcomes vary widely and depend on individual biology, disease severity, and treatment protocol.
Is the treatment safe?
Performed under strict clinical standards, stem cell therapy has demonstrated a favorable safety profile, but long-term outcomes are still being studied. Some types of cells are cultivated from patient’s somatic cells.
How long does it take to see results?
Potential biological changes may take from 3 – 6 months, consistent with the natural cycle of spermatogenesis.
How to understand how many stages of therapy are needed for treatment?
This is determined by the patient’s medical history and the cause of azoospermia.
After treatment, where are live sperm most often found: in the ejaculate or in TESE?
There is definitely a greater chance of finding active and living spermatozoa in the testicles during the TESU procedure.
Can stem cell therapy replace IVF or ICSI?
In most cases, it is considered complementary rather than a replacement for assisted reproductive technologies.